Engineers Gate Manager’s Verve Therapeutics VERV Stock Holding History

Engineers Gate Manager’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,256	Closed	-$205K	–	2566
2025 Q2	$205K	Buy	+18,256	New	+$104K	﹤0.01%	1889
2023 Q2	–	Sell	-26,720	Closed	-$385K	–	2056
2023 Q1	$385K	Buy	+26,720	New	+$523K	0.02%	1114

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Engineers Gate Manager's VERV Position: Q3 2025 in Review

Engineers Gate Manager sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 18,256 shares — an estimated $205K sold.

Engineers Gate Manager first reported a position in VERV in Q1 2023 and held it in 2 quarters. The position peaked at $385K in Q1 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Engineers Gate Manager reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Engineers Gate Manager sold 18,256 Verve Therapeutics shares in Q3 2025, an estimated $205K.
Engineers Gate Manager first reported a position in Verve Therapeutics in Q1 2023 and held it in 2 quarters.
Engineers Gate Manager's Verve Therapeutics position peaked at $385K in Q1 2023.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Engineers Gate Manager's 13F filing for Q3 2025, filed 14 Nov 2025.